阿托伐他汀对脑小血管病并认知功能损伤的作用研究(1)
【摘要】目的：探索脑小血管病并认知功能损伤患者应用托伐他汀治疗的临床效果。方法：180例脑小血管病并认知功能损伤患者随机分组，对照组90例均接受常规治疗，研究组90例均在此基础上予以阿托伐他汀治疗。结果：干预后，两组三酰甘油、脂蛋白a、低密度脂蛋白胆固醇以及游离脂肪酸相关血脂指标均显著降低(P<0.05)，研究组显著低于对照组(P<0.05)。两组认知功能及日常生活能力评分均显著提升(P<0.05)，研究组显著超过对照组(P<0.05)。研究组总有效率为91.11%，显著超过对照组的71.11%(P<0.05)。两组不良反应发生率均较低且接近(P>0.05)。结论：脑小血管病并认知功能损伤患者应用托伐他汀治疗可有效降低血脂指标，减轻认知功能损伤，提高日常生活能力，具有较高安全性。
【关键词】脑小血管病;认知障碍;阿托伐他汀
[Abstract]Objective：To explore the clinical effect of torvastatin in patients with cerebrovascular disease and cognitive impairment.Methods：180 patients with cerebrovascular disease and cognitive impairment were randomly divided into control group (n = 90) and control group (n = 90). On this basis， 90 patients in the study group were treated with Atto vastatin. Results： After intervention， the levels of triglyceride， lipoprotein a， low density lipoprotein cholesterol and free fatty acid-related lipids in the two groups were significantly lower than those in the control group (P < 0.05)， but significantly lower in the study group than in the control group (P < 0.05). The scores of cognitive function and activity of daily living in the two groups were significantly increased (P < 0.05)， and the scores in the study group were significantly higher than those in the control group (P < 0.05). The total effective rate of the study group was 91.11%， which was significantly higher than that of the control group (71.11%， P < 0.05). The incidence of adverse reactions in both groups was low and close (P > 0.05).Conclusion： The application of torvastatin in patients with cerebrovascular disease and cognitive impairment can effectively reduce the blood lipid index， alleviate the cognitive impairment and improve the ability of daily living (ADL). It is safe to use torvastatin in the treatment of patients with cognitive impairment.
, 百拇医药
[Key words]Cerebrovascular disease; cognitive impairment; Atto vastatin
【中圖分类号】R715【文献标识码】A 【文章编号】2095-6851(2019)06-037-01
近年来，由于多种因素的交互作用，导致脑小血管病具有较高的发病率，严重影响患者健康以及生命安全。该病主要表现为认知障碍。研究显示，大约50%以上的脑小血管病患者最终发展为血管性痴呆，进而丧失正常自主神经功能以及生活自理能力，严重影响生存质量[1]。目前条件下，针对该类患者实施治疗，主要应用多奈哌齐以及阿司匹林等常规药物方式。经该方案可以有效降低血小板凝聚率，改善脑部血流情况，但无法有效调节血脂以及减轻外周血管功能损伤[2]。我院积极开展研究，探索研究针对脑小血管病并认知功能损伤患者应用托伐他汀治疗的临床效果，取得了有价值的经验。
1 资料与方法
1.1 一般资料 本研究纳入对象均为我院2018年1月-12月期间收治的脑小血管病并认知功能损伤患者，共计180例。所有患者均具有相关临床指征并经检查确诊。已对合并免疫系统疾病者、肾脏疾病者、脑水肿脑梗死者予以排除，同时排除合并低血压、心源性休克者等其他类型患者。含男88例、女92例;年龄41-77岁，平均(57.5±6.5)岁。在具体疾病类型方面，含动脉粥样硬化58例、脑动脉血栓61例、脑动脉炎61例。经同意，随机分组，各90例。两组患者一般资料数据无显著性差异(P>0.05)。, 百拇医药(荣怡)
【关键词】脑小血管病;认知障碍;阿托伐他汀
[Abstract]Objective：To explore the clinical effect of torvastatin in patients with cerebrovascular disease and cognitive impairment.Methods：180 patients with cerebrovascular disease and cognitive impairment were randomly divided into control group (n = 90) and control group (n = 90). On this basis， 90 patients in the study group were treated with Atto vastatin. Results： After intervention， the levels of triglyceride， lipoprotein a， low density lipoprotein cholesterol and free fatty acid-related lipids in the two groups were significantly lower than those in the control group (P < 0.05)， but significantly lower in the study group than in the control group (P < 0.05). The scores of cognitive function and activity of daily living in the two groups were significantly increased (P < 0.05)， and the scores in the study group were significantly higher than those in the control group (P < 0.05). The total effective rate of the study group was 91.11%， which was significantly higher than that of the control group (71.11%， P < 0.05). The incidence of adverse reactions in both groups was low and close (P > 0.05).Conclusion： The application of torvastatin in patients with cerebrovascular disease and cognitive impairment can effectively reduce the blood lipid index， alleviate the cognitive impairment and improve the ability of daily living (ADL). It is safe to use torvastatin in the treatment of patients with cognitive impairment.
, 百拇医药
[Key words]Cerebrovascular disease; cognitive impairment; Atto vastatin
【中圖分类号】R715【文献标识码】A 【文章编号】2095-6851(2019)06-037-01
近年来，由于多种因素的交互作用，导致脑小血管病具有较高的发病率，严重影响患者健康以及生命安全。该病主要表现为认知障碍。研究显示，大约50%以上的脑小血管病患者最终发展为血管性痴呆，进而丧失正常自主神经功能以及生活自理能力，严重影响生存质量[1]。目前条件下，针对该类患者实施治疗，主要应用多奈哌齐以及阿司匹林等常规药物方式。经该方案可以有效降低血小板凝聚率，改善脑部血流情况，但无法有效调节血脂以及减轻外周血管功能损伤[2]。我院积极开展研究，探索研究针对脑小血管病并认知功能损伤患者应用托伐他汀治疗的临床效果，取得了有价值的经验。
1 资料与方法
1.1 一般资料 本研究纳入对象均为我院2018年1月-12月期间收治的脑小血管病并认知功能损伤患者，共计180例。所有患者均具有相关临床指征并经检查确诊。已对合并免疫系统疾病者、肾脏疾病者、脑水肿脑梗死者予以排除，同时排除合并低血压、心源性休克者等其他类型患者。含男88例、女92例;年龄41-77岁，平均(57.5±6.5)岁。在具体疾病类型方面，含动脉粥样硬化58例、脑动脉血栓61例、脑动脉炎61例。经同意，随机分组，各90例。两组患者一般资料数据无显著性差异(P>0.05)。, 百拇医药(荣怡)